– SLN360 reduced Lp(a) – a key genetic risk factor for heart disease – by up to 98% with reductions of up to 81% persisting at 150 days – Results were simultaneously published in The Journal of the American Medical Association (JAMA) […]
Tag: APOLLO Trial
Recent
New Data Demonstrates Vektor Medical’s AI-Powered vMap Algorithm Achieves 91% Accuracy in Distinguishing Epicardial and Endocardial Ventricular Tachycardia, Markedly Surpassing Visual ECG Analysis
Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
Genomadix Inc. Enters into Collaboration with Mayo Clinic on Precision Medicine for Telestroke
Popular
- No commented posts yet